Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Br J Dermatol, 2020.
Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group.
Read publication: Br J Dermatol
Related
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study...
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic ...
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-b...
Contact Us
Find Us
The University of Manchester
First Floor Bright Building
Manchester Science Park
Manchester
M15 6GZ
0 Comments